作者: Stephen D Stroupe , Tracey L Colpitts
DOI: 10.2217/PME.09.70
关键词:
摘要: Personalized medicine attempts to provide the right drug patient. In oncology, mechanisms driving an individual's tumor need be identified for appropriate therapy selection. Progressing from biomarker characterization a population-based is necessary clinical trial design and success. This article will review recent EGF receptor trials in non-small-cell lung cancer colorectal cancer, defined subgroups demonstrate relationship between biomarkers efficacy (response rate) that can visualized with 'efficacy curve'. A method predicting therapeutic response of patients by tests provided.